| Literature DB >> 25385865 |
Eva H Clark1, Morgan A Marks2, Robert H Gilman2, Antonio B Fernandez2, Thomas C Crawford2, Aaron M Samuels2, Alicia I Hidron2, Gerson Galdos-Cardenas2, Gilberto Silvio Menacho-Mendez2, Ricardo W Bozo-Gutierrez2, Diana L Martin2, Caryn Bern2.
Abstract
Approximately 8 million people have Trypanosoma cruzi infection, and nearly 30% will manifest Chagas cardiomyopathy (CC). Identification of reliable early indicators of CC risk would enable prioritization of treatment to those with the highest probability of future disease. Serum markers and electrocardiogram (EKG) changes were measured in 68 T. cruzi-infected individuals in various stages of cardiac disease and 17 individuals without T. cruzi infection or cardiac disease. T. cruzi-infected individuals were assigned to stage A (normal EKG/chest x-ray [CXR]), B (abnormal EKG/normal CXR), or C (abnormal EKG/cardiac structural changes). Ten serum markers were measured using enzyme-linked immunosorbent assay (ELISA)/Luminex, and QRS scores were calculated. Higher concentrations of transforming growth factor-β1 (TGFβ1), and TGFβ2 were associated with stage B compared with stage A. Matrix Metalloproteinase 2 (MMP2), Tissue Inhibitors of MMP 1, QRS score, and Brain Natriuretic Protein rose progressively with increasing CC severity. Elevated levels of several markers of cardiac damage and inflammation are seen in early CC and warrant additional evaluation in longitudinal studies. © The American Society of Tropical Medicine and Hygiene.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25385865 PMCID: PMC4347387 DOI: 10.4269/ajtmh.14-0246
Source DB: PubMed Journal: Am J Trop Med Hyg ISSN: 0002-9637 Impact factor: 2.345